Security key
230031106
Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)
CUSIP: 230031106
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 4,072,496
- Total 13F value
- $62,516,748
- Share change
- +640,979
- SEC-reported price per share
- $15.35
- Number of holders
- 35
- Value change
- +$9,431,036
- Number of buys
- 18
- Number of sells
- 10
- Shares outstanding
- 61,708,871
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
35
Top holders
10
CGEM full security history
Ownership snapshot
Full 13F holder table
Cullinan Therapeutics, Inc. SEC filings
Cullinan Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 230031106
Recent filing periods:
Ownership snapshot
Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
MPM BioImpact LLC
Comparable rows
8/15
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
7 rows are not safely comparable across share classes.
13D/G row: Lynx1 Capital Management LP
Showing 1-6 of 15 holder rows.
Quick read
Lynx1 Capital Management LP leads the comparable SEC ownership view at 14%.
8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership
Top 5
Lynx1 Capital Management LP
14%
BIOTECHNOLOGY VALUE FUND L P
10%
PRICE T ROWE ASSOCIATES INC /MD/
6.2%
STATE STREET CORP
6%
Kynam Capital Management, LP
5.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
14%
Reported 13D/G
· 08 Oct 2025
|
$163,225,335
8,963,500 shares
|
— | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
Reported 13D/G
· 30 Jun 2026
|
$119,631,397
6,491,123 shares
|
+$6,075,523 | 30 Jun 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
T. Rowe Price Associates, Inc. · Company
|
6.2%
Reported 13D/G
· 30 Jun 2026
|
$70,512,258
3,825,950 shares
|
$0 | 30 Jun 2026 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
6%
Reported 13D/G
· 30 Jun 2026
|
$67,612,796
3,668,627 shares
|
$0 | 30 Jun 2026 |
| Kynam Capital Management, LP |
13F
13D/G
Company
|
5.3%
Reported 13D/G
· 31 Dec 2025
|
$56,708,344
3,114,132 shares
|
— | 30 Jun 2026 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
5%
Reported 13D/G
· 30 Sep 2025
|
$17,357,187
2,927,013 shares
|
$0 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
35
Shares
4,072,496
Rows available
35
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
182
Q3 2026 holders
35
Holder diff
-147
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend